These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 15464913)

  • 1. Vaccines in leukemia.
    Lu S; Wieder E; Komanduri K; Ma Q; Molldrem JJ
    Adv Pharmacol; 2004; 51():255-70. PubMed ID: 15464913
    [No Abstract]   [Full Text] [Related]  

  • 2. Cancer immunotherapy targeting the telomerase reverse transcriptase.
    Huo LF; Tang JW; Huang JJ; Huang PT; Huang CF; Kung HF; Lin MC
    Cell Mol Immunol; 2006 Feb; 3(1):1-11. PubMed ID: 16549043
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunotherapeutic peptide vaccination with leukemia-associated antigens.
    Rusakiewicz S; Molldrem JJ
    Curr Opin Immunol; 2006 Oct; 18(5):599-604. PubMed ID: 16870418
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Vaccination for leukemia.
    Molldrem JJ
    Biol Blood Marrow Transplant; 2006 Jan; 12(1 Suppl 1):13-8. PubMed ID: 16399579
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cancer vaccines and immunotherapies: emerging perspectives.
    Henderson RA; Mossman S; Nairn N; Cheever MA
    Vaccine; 2005 Mar; 23(17-18):2359-62. PubMed ID: 15755628
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dendritic cell vaccines in acute leukaemia.
    Duncan C; Roddie H
    Best Pract Res Clin Haematol; 2008 Sep; 21(3):521-41. PubMed ID: 18790453
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Xenogenic cancer vaccines.
    Potebnya GP; Symchych TV; Lisovenko GS
    Exp Oncol; 2010 Jul; 32(2):61-5. PubMed ID: 20693963
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Recent developments in therapeutic cancer vaccines.
    Morse MA; Chui S; Hobeika A; Lyerly HK; Clay T
    Nat Clin Pract Oncol; 2005 Feb; 2(2):108-13. PubMed ID: 16264883
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Peptide vaccines for patients with acute myeloid leukemia.
    Schmitt M; Casalegno-Garduño R; Xu X; Schmitt A
    Expert Rev Vaccines; 2009 Oct; 8(10):1415-25. PubMed ID: 19803762
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cancer vaccines for patients with acute myeloid leukemia--definition of leukemia-associated antigens and current clinical protocols targeting these antigens.
    Greiner J; Döhner H; Schmitt M
    Haematologica; 2006 Dec; 91(12):1653-61. PubMed ID: 17145602
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical trials targeting lung cancer with active immunotherapy: the scope of vaccines.
    Raez LE; Santos ES; Mudad R; Podack ER
    Expert Rev Anticancer Ther; 2005 Aug; 5(4):635-44. PubMed ID: 16111464
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antigens for cancer immunotherapy.
    Neller MA; López JA; Schmidt CW
    Semin Immunol; 2008 Oct; 20(5):286-95. PubMed ID: 18951039
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunotherapy of hematological malignancies using dendritic cells.
    Van de Velde AL; Berneman ZN; Van Tendeloo VF
    Bull Cancer; 2008 Mar; 95(3):320-6. PubMed ID: 18390412
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cancer vaccines: what do we need to measure in clinical trials?
    Kudrin A
    Hum Vaccin Immunother; 2014; 10(11):3236-40. PubMed ID: 25483508
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tumor vaccines--application to childhood cancer.
    Roskrow MA; Zibert A; Souquet M; Dilloo D
    Klin Padiatr; 1999; 211(4):336-46. PubMed ID: 10472573
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tumor antigens as surrogate markers and targets for therapy and vaccines.
    Dalgleish A; Pandha H
    Adv Cancer Res; 2007; 96():175-90. PubMed ID: 17161680
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Novel immunotherapeutic approaches to glioma.
    Yamanaka R
    Curr Opin Mol Ther; 2006 Feb; 8(1):46-51. PubMed ID: 16506525
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Current approaches in ovarian cancer vaccines.
    Reinartz S; Wagner U
    Minerva Ginecol; 2004 Dec; 56(6):515-27. PubMed ID: 15729204
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunity to melanoma antigens: from self-tolerance to immunotherapy.
    Slingluff CL; Chianese-Bullock KA; Bullock TN; Grosh WW; Mullins DW; Nichols L; Olson W; Petroni G; Smolkin M; Engelhard VH
    Adv Immunol; 2006; 90():243-95. PubMed ID: 16730266
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeting targeted therapies.
    Shingler W; Harrop R
    Immunotherapy; 2010 Nov; 2(6):745-8. PubMed ID: 21091104
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.